Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 469.20 INR
Change Today +1.45 / 0.31%
Volume 698.9K
As of 6:25 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOS) Snapshot

Open
468.95
Previous Close
467.75
Day High
476.00
Day Low
468.00
52 Week High
09/19/14 - 515.00
52 Week Low
01/7/15 - 402.30
Market Cap
93.8B
Average Volume 10 Days
1.0M
EPS TTM
26.22
Shares Outstanding
200.0M
EX-Date
04/9/15
P/E TM
17.9x
Dividend
5.00
Dividend Yield
1.07%
Current Stock Chart for BIOCON LTD (BIOS)

Related News

No related news articles were found.

biocon ltd (BIOS) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOS) Details

Biocon Limited, an integrated healthcare company, develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, and narrow spectrum antibiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of cardiology, diabetology, oncology, nephrology, cardiology, immunotherapy, and comprehensive care; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company’s principal brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It serves its customers in approximately 85 countries. The company was founded in 1978 and is headquartered in Bengaluru, India.

7,528 Employees
Last Reported Date: 06/23/15
Founded in 1978

biocon ltd (BIOS) Top Compensated Officers

Chief Executive Officer, Joint Managing Direc...
Total Annual Compensation: 25.5M
Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.7M
Chief Financial Officer and President of Fina...
Total Annual Compensation: --
Vice Chairman, Member of Share Transfer Commi...
Total Annual Compensation: 14.8M
Senior Vice President
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

biocon ltd (BIOS) Key Developments

Biocon Limited Amends its Articles of Association

Biocon Limited amended its articles of association in line with the new companies Act 2003 at its AGM held on July 24, 2015.

Biocon Limited Reports Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2015

Biocon Limited reported unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 7,789.6 million against INR 7,188.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,543.8 million against INR 1,220.1 million a year ago. Profit from ordinary activities before tax was INR 1,734.8 million against INR 1,380.6 million a year ago. Net profit for the period was INR 1,365.3 million or INR 6.31 per diluted share against INR 1,071.7 million or INR 5.20 per diluted share a year ago. Net profit after tax and minority interest was INR 1,262.4 million against INR 1,029.1 million a year ago. Revenue was INR 8,570 million against INR 7,420 million for the same period a year ago. EBITDA was INR 2,360 million against INR 1,910 million for the same period a year ago. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 5,151.1 million against INR 5,346.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,000.1 million against INR 856.6 million a year ago. Profit from ordinary activities before tax was INR 1,331.0 million against INR 971.3 million a year ago. Net profit for the period was INR 1,034.3 million or INR 5.17 per diluted share against INR 746.3 million or INR 3.77 per diluted share a year ago.

Biocon Limited Proposes Interim Dividend for the Year Ended March 31, 2015

Biocon Limited proposed payment of interim dividend of INR 5.00 per equity share (100%) as dividend for the year ended March 31, 2015, for approval at the AGM to be held on July 24, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 469.20 INR +1.45

BIOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.89 USD +0.325
Cambrex Corp $52.10 USD +2.38
Croda International PLC 3,093 GBp +14.00
Divi's Laboratories Ltd 1,997 INR +36.45
Piramal Enterprises Ltd 944.05 INR +38.90
View Industry Companies
 

Industry Analysis

BIOS

Industry Average

Valuation BIOS Industry Range
Price/Earnings 17.9x
Price/Sales 2.9x
Price/Book 2.7x
Price/Cash Flow 12.4x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.